A Multisite Trial of ACQUIREc Therapy

Not Applicable

Completed

• Conditions: Hemiparetic Cerebral Palsy

• Registration Number: NCT00991692
• Lead Sponsor: University of Alabama at Birmingham

Brief Summary

A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy services for 21 days. It was hypothesized that children receiving the higher therapy dosage would have greater and more clinically significant benefits from ACQUIREc Therapy but that both groups of children would benefit from the therapy services.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Primary Completion: 2009-08
• Status Verified: 2009-10
• Study Completion: 2009-10
• Study First Submitted: 2009-10-07
• Study First Submitted QC: 2009-10-07
• Last Update Submitted: 2009-10-07
• Study First Posted: 2009-10-08
• Last Update Posted: 2009-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Children 3-6 years of age
• Hemiparetic CP

Exclusion Criteria

• No prior CI therapy treatments
• No Botox for 6-months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Trial Locations

Locations (1)

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States